SAGE Labs Partners with Cofactor Genomics
News Oct 08, 2013
SAGE Labs Inc. announced that it will begin offering RNA-sequencing services as part of its SAGEspeed Custom Model Creation Platform. The sequencing and analysis portion of the RNA-seq studies will be performed by Cofactor Genomics, a leader in the field of RNA sequencing and analysis (RNA-seq).
Through the agreement, SAGE Labs, who has rights to use Zinc Finger Nuclease (ZFN) and CRISPR/cas9 technology to generate genetically modified mice, rats, and rabbits, will now be able to provide gene expression profiles on the resulting animal models. This enables researchers to identify genes that are turned on or off as a result of the genomic modification.
Clients of the RNA-seq services will receive an in-depth representation of expressed loci and differential expression of genes. These expression profiles lay the foundation for future experiments involving the animal model, for instance, studying how gene expression will change in response to certain treatments or conditions.
Kevin Gamber, PhD, Director of Marketing at SAGE Labs, explained “SAGE is very excited to offer RNA-seq expression profiling as a part of our SAGEspeed custom model generation services. Through this valuable addition, customers will not only receive their custom animal model, but also the relative gene expression level of every gene. You’ll instantly be able to know which genes and pathways are potentially affected in your model.”
Cofactor’s COO, Jon Armstrong, noted “Cofactor is pleased to offer our expertise in RNA sequencing to build off of SAGE’s genetically engineered models. Genomic characterization is the next step after animal model creation and RNA expression analysis will provide insight and confidence to an already excellent service. SAGE is not only a leader in the field but a fellow St. Louis company and we are delighted to be collaborating with them.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE